A Comparative Study of TECNIS Symfony Plus IOL and a Trifocal IOL

Overview

This is a multicenter, prospective, randomized, subject- and evaluator-masked, bilateral-implant study conducted at up to 15 sites worldwide. A total of up to 280 subjects will be randomized in a 1:1 ratio for implantation with either the TECNIS Symfony plus IOL Model ZHR00V or the Trifocal IOL. This will ensure that data from at least 100 subjects in the TECNIS Symfony plus lens group and at least 100 subjects in the Trifocal lens group will be available for analysis at the 6-month follow-up timepoint. All subjects will be followed for up to 6 months postoperative.

Full Title of Study: “A Comparative Clinical Evaluation of a New TECNIS® Presbyopia-correcting Intraocular Lens Against a Trifocal Intraocular Lens”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Care Provider)
  • Study Primary Completion Date: January 31, 2021

Interventions

  • Device: TECNIS Symfony plus IOL Model ZHR00V
    • IOL replaces the natural lens removed during cataract surgery
  • Device: Trifocal Intraocular lens
    • IOL replaces the natural lens removed during cataract surgery

Arms, Groups and Cohorts

  • Experimental: Investigational Lens
    • TECNIS Symfony plus IOL Model ZHR00V
  • Active Comparator: Control Lens
    • Trifocal Intraocular Lens

Clinical Trial Outcome Measures

Primary Measures

  • Binocular distance-corrected VA of 20/25
    • Time Frame: 3 months
    • Percent of subjects who achieve binocular distance-corrected VA of 20/25 (6.7.5) Snellen or better at far, intermediate, and near (40 cm)
  • Binocular uncorrected VA of 20/32
    • Time Frame: 3 months
    • Percent of subjects who achieve binocular uncorrected VA of 20/32 or better at far and near (40 cm)

Participating in This Clinical Trial

Inclusion Criteria

(all criteria apply to both eyes):

  • Age 22 and older
  • Bilateral cataracts or clear crystalline lenses for which posterior chamber IOL implantation has been planned
  • Potential postoperative best corrected distance visual acuity (BCDVA) of 0.66 decimal (20/30 or 6/9 Snellen) or better
  • Predicted postoperative corneal astigmatism less than 1.0 D, including posterior corneal astigmatism (PCA)
  • Clear intraocular media other than cataract in each eye
  • Availability, willingness and sufficient cognitive awareness to comply with examination procedures
  • Ability to understand, read, and write English or the local language in which the informed consent and questionnaires are provided
  • Written informed consent for participation in the study and data protection.

Exclusion Criteria

  • (including device labeling, all criteria apply to both eyes):
  • Require an intraocular lens power outside the available range of +14.0 to +26.0 D
  • Irregular corneal astigmatism (as evaluated by topography)
  • Prior corneal refractive (LASIK, LASEK, RK, PRK, etc.) or intraocular surgery, including prophylactic peripheral iridotomies and peripheral laser retinal repairs
  • Corneal abnormalities such as stromal, epithelial or endothelial dystrophies (e.g., any observed guttata) that are predicted to cause visual acuity loss to a level worse than 0.66 decimal (20/30 or 6/9 Snellen) during the study
  • Inability to achieve keratometric stability for contact lens wearers
  • Recent ocular trauma or ocular surgery that is not resolved/stable or may affect visual outcomes or increase risk to the subject
  • Pupil abnormalities that may affect visual outcomes or increase risk to the subject
  • Subjects with diagnosed degenerative visual disorders (e.g., macular degeneration or other retinal disorders) that are predicted to cause visual acuity loss to a level worse than 0.66 decimal (20/30 or 6/9 Snellen) during the study
  • Subjects with conditions associated with increased risk of zonular rupture, including capsular or zonular abnormalities that may lead to IOL decentration or tilt, such as pseudoexfoliation, trauma, or posterior capsule defects
  • Use of systemic or ocular medications that, in the opinion of the investigator, may affect vision
  • Prior, current, or anticipated use during the 6-month study of tamsulosin or silodosin that may, in the opinion of the investigator, confound the outcome or increase the risk to the subject (e.g., poor dilation or a lack of adequate iris structure to perform standard cataract surgery)
  • Poorly-controlled diabetes or hypertension that, in the opinion of the investigator, may mpact visual outcome or increase the risk to the subject
  • Acute, chronic, or uncontrolled systemic or ocular disease or illness that, in the opinion of the investigator, would increase the operative risk or confound the outcome(s) of the study (e.g., immunocompromised, connective tissue disease, suspected glaucoma, glaucomatous changes in the fundus or visual field, ocular inflammation, etc.). Note: controlled ocular hypertension without glaucomatous changes (optic nerve cupping and visual field loss) is acceptable.
  • Known ocular disease or pathology that, in the opinion of the investigator,
  • may affect visual acuity (e.g., ocular surface conditions)
  • may require surgical intervention during the study (macular degeneration, cystoid macular edema, diabetic retinopathy, uncontrolled glaucoma, etc.)
  • may be expected to require retinal laser treatment or other surgical intervention during the study (macular degeneration, cystoid macular edema, diabetic retinopathy, etc.)
  • Pregnancy, planned pregnancy, presently lactating, or another condition associated with hormonal fluctuation that could lead to refractive changes
  • Concurrent participation or participation within 60 days prior to the preoperative visit in any other clinical trial
  • Desire for monovision correction

Gender Eligibility: All

Minimum Age: 22 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Johnson & Johnson Surgical Vision, Inc.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Devi Priya Janakiraman, OD, FAAO, Study Director, Johnson & Johnson Surgical Vision
  • Overall Contact(s)
    • Anne Buteyn, +1 949 505-2029, abuteyn@its.jnj.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.